Search

Displaying results 7221 - 7230 of 10000 in total
  1. Drug

    Penequinine, Penehyclidine

    go.drugbank.com/drugs/DB16287
    Investigational

    Penequinine, Penehyclidine is under investigation in clinical trial NCT02644876 (Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications).

  2. Drug

    Pratosartan

    go.drugbank.com/drugs/DB20100
    Experimental

    Pratosartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Pratosartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

  3. Drug

    Ripisartan

    go.drugbank.com/drugs/DB20229
    Experimental

    Ripisartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Ripisartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

  4. Drug

    Erythritol

    go.drugbank.com/drugs/DB04481
    Investigational

    Erythritol is a four-carbon sugar that is found in algae, fungi, and lichens. It is twice as sweet as sucrose and can be used as a coronary vasodilator.

  5. Drug

    Deutarserine

    go.drugbank.com/drugs/DB19057
    Investigational

    Deutarserine is under investigation in clinical trial NCT04158687 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia).

  6. Drug

    Crisugabalin

    go.drugbank.com/drugs/DB19300
    Investigational

    Crisugabalin is under investigation in clinical trial NCT06490484 (Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to

  7. Drug

    Urolithin A

    go.drugbank.com/drugs/DB15464
    Experimental

    Urolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.[A179494]

  8. Drug

    WX-554

    go.drugbank.com/drugs/DB21749
    Investigational

    WX-554 is under investigation in clinical trial NCT01581060 (Phase I/​II Dose-escalation Study to Investigate Safety and Pharmacokinetics/​ Pharmacodynamics of WX-554 in Patients With Solid Tumours).

  9. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27. … BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy

  10. Drug

    Iproniazid

    go.drugbank.com/drugs/DB04818
    ApprovedWithdrawn

    Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.